It’s the SYBIL mid-term review

Systems biology for the functional validation of genetic determinants of skeletal diseases

Looking forward to presenting all our excellent new data to the European Commission!

Newcastle – Manchester Research Day

Its that time of the year again and looking forward to another great meeting…………

SYBIL @ Lyon November 2014

Systems biology for the functional validation of genetic determinants of skeletal diseases

FP7-HEALTH-2013-INNOVATION-1

SYBIL held a very successful 1st Annual Meeting in the lovely city of Lyon from the 6th to 7th November

More photos and the Autumn Newsletter to follow shortly…..

But in the meantime we did meet Napoleon and Le Black Sheep

Who we believe may be related to our very own Yorkshire Black Sheep

 

SYBIL in the news 2014

SYBIL (Systems biology for the functional validation of genetic determinants of skeletal diseases)

It’s time for the first annual report on SYBIL’s scientific and dissemination activities. Here are some press articles for the last 12 months.

SYBIL is funded by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 602300

Have you ever wondered what SYBIL is….?

Then this is for you!

Kasia has prepared an excellent summary posterThe full poster can be downloaded here SYBIL lay poster.

Musculoskeletal Research Group – Public Engagement Day

 

 

SYBIL satellite meeting in Rotterdam on Sat 21st June

Please note that the meeting is restricted to young researchers (PhD and PostDocs) and it is fully catered and free to attend, provided that you have registered for the main MBE conference.

Nice try Albert……….

Bone Research Society – Rare Bone Diseases Workshop

One for the diary

Bone Research Society – Rare Bone Diseases Workshop

Venue: Rutland Hotel

In association with Arthritis Research UK Rare Bone Disease Topic Specific Group & Findacure

Objectives 

1. To discuss the relevance of research into rare diseases
2. To provide an opportunity for participants to hear more about some of the collaborations that have been set up to facilitate research into rare bone diseases
3. To look at opportunities to collaborate and pool ideas
4. To provide a networking opportunity

 Please click here for further details. 

There is a £15 charge for participation in this workshop, which includes a buffet supper.

BSR 2014 meeting details here.

SYBIL_UK Research Meeting on Thursday

Several members of the Manchester and Newcastle groups are having a research day tomorrow in Newcastle.

Lots to present and discuss.

Agenda here Newcastle Manchester Research Day.

‘ESDN’, ‘EuroGrow’ and ‘SYBIL’

‘ESDN’, ‘EuroGrow’ & ‘SYBIL’ – 15+ years of EU network approaches for diagnosis and research of rare skeletal diseases.

The European Skeletal Dysplasia Network (ESDN) was established in 2002 with EU FP5 funding as a pan-European research and diagnostic network for chondrodysplasias. ESDN was one of the first networks of expertise in rare diseases to use information and communication technologies for medical diagnosis. Between 2003-2013 ESDN has received over 2000 referrals through an on-line case-manager and 450 users have accessed ESDN from 45 different countries. ESDN successfully introduced a new paradigm to rare disease diagnosis and the international reach and impact of ESDN demonstrates how this network has transformed the diagnosis of genetic bone diseases worldwide.

EuroGrow (2007-2010) was funded by EU FP6 and provided proof-of-principle concept for a coordinated approach to studying disease mechanisms in rare skeletal diseases using genetic mouse models. The development of deep-phenotyping protocols and procedures for generating robust –omics profiles delivered important technical advances for these difficult disease and tissue systems.

Finally, EU FP7-funded SYBIL (2013-2018) is a large-scale collaborative project concentrating on the functional validation of genetic determinants of rare skeletal diseases and builds on the previous successes of ESDN and EuroGrow. In addition to refining disease mechanisms through deep-phenotyping of novel cell and animal models, SYBIL also has a strong translational component focused on developing new biomarkers and identifying therapeutic targets. This last approach will provide important new knowledge in preparation for Horizon2020.

See: www.ESDN.org & @ESDN_news; www.sybil-fp7.eu & @SYBIL_news